1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Venus Medtech (Hangzhou) Inc.

Venus Medtech (Hangzhou) Inc.

VMTHF
Venus Medtech (Hangzhou) Inc.US flagOther OTC
0.42
USD
- -
- -
186.06MMarket Cap
Venus Medtech (Hangzhou) Inc.
VMTHF
(Other OTC)

Recent

price

0.42

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.05
0.29
0.75
0.67
0.95
0.93
1.12
1.08
0.7
Revenue per Share
-0.4
-0.77
-1.22
-0.44
-0.85
-2.42
-1.61
-1.63
-0.93
Basic EPS, GAAP
-0.26
-0.45
-1.05
-0.88
-1.37
-2.07
-1.99
-0.04
-0.76
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.3
-0.52
-0.79
-1.55
-3.97
-5.57
-7.21
-8.14
Book Value per Share
0.15
-0.49
7.64
7.63
8.68
4.07
3.07
1.66
0.8
Tangible Book Value per Share
393
393
311
409
439
438
438
438
438
Basic Weighted Avg Shares
18
115
233
276
416
406
491
471
307
Sales/Revenue/Turnover
-847.18
-255.3
-136.69
-53.92
-65.4
-156.2
-116.22
-73.61
-106.72
Operating Margin (%)
6
10
29
38
52
112
125
111
97
Depreciation Expense
-157
-300
-381
-182
-374
-1,058
-704
-714
-408
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-861.77
-260.45
-163.21
-65.93
-89.85
-260.22
-143.22
-151.71
-132.89
Profit Margin (%)
26
-205
2,336
2,955
3,231
1,977
803
441
426
Working Capital
4
15
17
22
48
654
331
313
21
LT Debt
81
470
3,046
3,857
4,632
3,631
2,919
2,211
1,763
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-518.02
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-13.13%
-20.28%
Free Cash Flow
- -
355.96%
1,764.03%
Net Income, GAAP
- -
42.7%
-42.92%
Sales/Revenue/Turnover
- -
6.05%
-34.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
491
2024
- -
- -
- -
- -
471
2025
- -
- -
- -
- -
307

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.61
2024
- -
- -
- -
- -
-1.63
2025
- -
- -
- -
- -
-0.93

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
EOFLOW Co.,Ltd. (294090.KQ)
Isoray, Inc. (ISR)
ProSomnus, Inc. (OSA)
BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)
Demant A/S (DEMANT.CO)
Delta Asia International Corporation (6762.TWO)
Business
Venus Medtech (Hangzhou) Inc. specializes in the research, development, and commercialization of advanced transcatheter heart valve medical solutions, serving patients across Mainland China and internationally. The company offers a diverse portfolio, including its VenusA-Valve system for treating severe aortic stenosis, along with the enhanced VenusA-Plus and VenusA-Pro transcatheter aortic valve replacement (TAVR) devices. For pulmonary valve dysfunction, the VenusP-Valve stands out as a pioneering self-expanding transcatheter pulmonary valve replacement (TPVR) system, which has achieved approvals in both China and Europe and is currently undergoing a pivotal clinical study in the United States. Beyond its established products, the company is actively developing next-generation dry-valve TAVR candidates like Venus-Vitae and Venus-PowerX, alongside innovative transcatheter systems such as Cardiovalve for both mitral and tricuspid valve replacement therapies. Venus Medtech also provides the Liwen RF ablation system for hypertrophic cardiomyopathy and is advancing renal denervation devices for hypertension management. Complementary products include the V8/TAV8 balloon aortic valvuloplasty catheters and the TriGUARD3 cerebral embolic protection device, designed to safeguard against brain damage during TAVR and other intricate structural heart procedures. Established in 2009, Venus Medtech is headquartered in Hangzhou, People's Republic of China, and continues to expand its global footprint and clinical innovations.

Company News

APIChat

  • prnewswire.com

    Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

  • prnewswire.com

    Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

  • prnewswire.com

    Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

  • prnewswire.com

    Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval